Wat waren in 2018 de belangrijkste wetenschappelijke ontwikkelingen en hoe vertaalt die nieuwe kennis zich in de dagelijkse praktijk? Het 13e Jaarsymposium Neurologie vond plaats op 16 januari 2019 in het NBC Congrescentrum Nieuwegein, onder voorzitterschap van dr. Vincent Odekerken, neuroloog Amsterdam UMC en dr. Kiril van Veen, neuroloog in het Alrijne Ziekenhuis te Leiden.
Bronnen:
- Voon V, et al. Functional neuroanatomy and neurophysiology of functional neurological disorders (conversion disorder). J Neuropsychiatry Clin Neurosci. 2016;28:168-90.,Salm SMA van der, et al. Clinical decision-making in functional and hyperkinetic movement disorders. Neurology. 2017;88; DOI: https://doi.org/10.1212/WNL.0000000000003479,Salm SMA van der, et al. Clinician and patient perceptions of free will in movement disorders: Mind. J Neurol Neurosurg Psychiatry. 2017;88;532-3.,Raul G, et al. Thrombectomy 6 to 24 Hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018; 378:11-21.,Albers GW, et al. A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3) Int J Stroke. 2017;12:896-905.,Gregory W, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018; 378:708-18.,Fisher RS, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58:531-42.,Wang S. Application of MRI post-processing in presurgical evaluation of non-lesional cingulate epilepsy. Front Neurol. 2018;9:1013. doi: 10.3389/fneur.2018.01013,Devinsky O, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Eng J Med. 2017;376:2011-20.,Devinsky O, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome N Engl J Med. 2018;378:1888-97.,Emile Keuter, Man-made diseases. Medisch Contact 20 augustus 2015,Ongaro G, Kaptchuk TJ. Symptom reduction, placebo effects, and the Bayesian brain. Pain. 2019;160:1-4.,Greef BTA de, et al. Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trial–the LENSS study. Trials. 2016;17:306.,Namer B, et al. Pain relief in a neuropathy patient by lacosamide: Proof of principle of clinical translation from patient-specific iPS cell-derived nociceptors EBioMedicine. 2019;39:401-8.,Jack CR et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535-62.,McCleery J, et al. When is Alzheimer’s not dementia—Cochrane commentary on The National Institute on Ageing and Alzheimer’s Association Research Framework for Alzheimer’s Disease. Age and Ageing 2018; https://doi.org/10.1093/ageing/afy167.,Schermer MHN, Richard E. On the conceptualization of Alzheimer’s disease. Bioethics 2018; https://doi.org/10.1111/bioe.12516.,Global Burden of Diseases 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 http://dx.doi.org/10.1016/ S1474-4422(18)30403-4.,Livingston G. et al. Dementia prevention, intervention, and care. Lancet. 2017;390:2673-734.